ClinicalTrials.gg
CompletedNCT06415214SOLID-DKDUpdated Jan 5, 2026

Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes

A Phase 2 interventional study of Placebo and HRS-7535 in Diabetic Kidney Disease, Type 2 Diabetes, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Diabetic Nephropathies with a site in China — 22 open to participants now, 30 under way, none of them phase 3. Diabetic Nephropathies · China.

Enrollment
16th of 52
281 · median 122
Started
2024
with 5 others
Phase 2
7 of 75
1 open now
Registered
54th of 75
by date

Among the 75 studies in Diabetic Nephropathies with a site in China, this one is the 16th largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2024, is one of 7 in phase 2, and was the 54th registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 75 studies in Diabetic Nephropathies with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetic Nephropathies with a site in China, or all of them as a file.
02

Study summary

The study is a 16-week multicenter, randomized, double-blind, placebo-controlled, parallel-designed Phase II clinical study. The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in subjects with diabetic kidney disease in type 2 diabetes.

03

Conditions studied

  • Diabetic Kidney Disease, Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, 18-75 years of age at the time of signing ;
  2. Body weight ≥50 kg, 20.0 kg/m2 ≤ ≤40.0 kg/m2;
  3. Diabetic kidney disease was diagnosed, and the ≥30 mL/min/1.73 m2;
  4. Had a history of T2DM at least 3 months, or had diabetic retinopathy as assessed by the investigators;
  5. UACR ≥300 and \<3000 mg/g;
  6. ≥6.5% and ≤10.0%;
  7. ACEI/ARB was used for ≥3 months and ACEI/ARB was stabilized at either the maximum recommended dose (reference to the drug label) or the maximum tolerated dose within 4 weeks;
  8. Use hypoglycemic drugs for ≥3 months (the dosage of SGLT2i remains stable if used);
  9. Able and willing to provide a written informed consent;

Exclusion criteria

Exclusion Criteria:

  1. Have type 1 diabetes mellitus or specific type of diabetes;
  2. Acute kidney injury or dialysis treatment within 6 months;
  3. Kidney transplantation is planned during the trial;
  4. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening;
  5. Any organ-system developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix;
  6. history of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;
  7. Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
281 participants (actual)

Study arms

  • Placebo comparator
    Group A,Subjects will receive Placebo administered orally

    Drug: Placebo

  • Experimental
    Group B,Subjects will receive HRS-7535 administered orally

    Drug: HRS-7535

  • Experimental
    Group C,Subjects will receive escalated HRS-7535 administered orally

    Drug: HRS-7535

Interventions

06

What researchers measure

Primary outcomes

  1. Ratio of UACR at week 16 to UACR at baseline

    Time frame: at Week 16

Secondary outcomes

  1. 24 hour urine analysis results at Week 16

    Time frame: at Week 16

  2. Proportion of subjects with a 30% decrease in UACR from baseline at Week 16

    Time frame: at Week 16

  3. Change from baseline in eGFR at Week 16

    Time frame: at Week 16

  4. Change from baseline in HbA1c at Week 16

    Time frame: at Week 16

  5. Proportion of subjects reaching the target of HbA1c (<7.0%、<6.5%) at Week 16

    Time frame: at Week 16

  6. Change from baseline in FPG at Week 16

    Time frame: at Week 16

  7. Change from baseline in insulin at Week 16

    Time frame: at Week 16

  8. Change from baseline in c-peptide at Week 16

    Time frame: at Week 16

  9. Change from baseline in body weight at Week 16

    Time frame: at Week 16

  10. Proportion of subjects receiving glycemic rescue medicine at Week 16

    Time frame: at Week 16

  11. A summary of adverse events, including serious adverse events (SAEs), and hypoglycemic event at Week 16

    Time frame: at Week 16

07

Study locations

1 site
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

References and documents

Publications

  • Lv R, Peng L, Xu Y, Du X, Liu H, Wu H, Zhang Y, Li Q, Jiao X, Piao C, Yang S, Lin X, Li L, Ye Z, Chen J; SOLID-DKD Investigator Groupl; SOLID-DKD Investigator Group. Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial. EClinicalMedicine. 2026 Jul 9;97:104045. doi: 10.1016/j.eclinm.2026.104045. eCollection 2026 Jul. PubMed 42472282 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jul 2025, 12 months.

Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 12 months is below that.

Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 16, 2024
StartActual
Jun 21, 2024
Primary completionActual
Jul 15, 2025
CompletionActual
Jul 25, 2025
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06415214
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Jun 21, 2024
Primary completion
Jul 15, 2025
Completion
Jul 25, 2025
Last update
Jan 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Safiglipron

Start the discussion